Results 21 to 30 of about 20,527 (318)
BMC Pulmonary Medicine, 2023 Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small-to-medium vessel vasculitis associated ...
Isao Suzaki +6 more
doaj +1 more source
How Can Dupilumab Cause Eosinophilic Pneumonia?
Biomolecules, 2022 Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are limited in previous studies. Herein, we report two cases in which EP developed subsequent to the administration of dupilumab for eosinophilic chronic rhinosinusitis ...
Momoko Kurihara +14 more
doaj +1 more source
Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]
, 2019 Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke +4 more
core +1 more source
Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status [PDF]
, 2023 Background Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's efficacy in patients from the TRAVERSE study with or without evidence of allergic asthma and type 2
Altincatal, Arman +11 more
core +1 more source
Canadian Journal of Health Technologies, 2021 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire +3 more sources
Shrinkage estimation for dose-response modeling in phase II trials with multiple schedules
, 2020 Recently, phase II trials with multiple schedules (frequency of administrations) have become more popular, for instance in the development of treatments for atopic dermatitis.
Friede, Tim +2 more
core +1 more source
Dupilumab-Associated Sezary Syndrome
Indian Journal of Dermatology, 2023 Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for AD, to our knowledge only one patient has been ...
Austin Hamp +3 more
openaire +3 more sources
Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report
SAGE Open Medical Case Reports, 2020 A 36-year-old Caucasian female with a long history of atopic dermatitis presented with multiple flares eventually leading to dupilumab therapy. Five months into the dupilumab therapy, she presented with well-demarcated erythematous plaques with silvery ...
Ho Seung Kim, Jensen Yeung
doaj +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Качественная клиническая практика, 2022 Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source
Diagnosis and management of eosinophilic asthma: a US perspective. [PDF]
, 2014 Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and ...
Doherty, Taylor A, Walford, Hannah H
core +1 more source